{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:58:59Z","timestamp":1790344739553,"version":"4.1.0"},"reference-count":124,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In recent years, minimal residual disease (MRD) testing has emerged as a powerful prognostic tool in multiple myeloma. Multiple meta-analyses have demonstrated that achieving MRD negativity is associated with significantly improved progression-free survival (PFS), leading to its acceptance as a surrogate endpoint in clinical trials to support accelerated drug approval. Looking forward, MRD status is poised to be incorporated into treatment decision-making; to guide escalation and de-escalation of therapy with the aims of improved progression free survival with limited treatment toxicity. In this review article, we provide an overview of the current modalities available for MRD testing, including bone marrow, peripheral blood, and imaging-based techniques. We examine the prognostic significance of MRD status, with a focus on the impact of sustained MRD negativity, outcomes with MRD resurgence, and the depth of MRD negativity on progression free survival. Finally, we discuss the rapidly evolving landscape of MRD-adapted clinical trials and how these studies are informing the development of response-adapted treatment strategies.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1932648","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:01:23Z","timestamp":1790341283000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Minimal residual disease in multiple myeloma: the movement towards response-adapted therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Kenneth JC","family":"Lim","sequence":"first","affiliation":[{"name":"The Australian Centre for Blood Diseases, Monash University, Melbourne","place":["VIC, Australia"]},{"name":"Department of Haematology, The Alfred Hospital, Melbourne","place":["VIC, Australia"]},{"name":"Department of Haematology, The Northern Hospital, Epping","place":["VIC, Australia"]},{"name":"Department of Haematology, St Vincent\u2019s Hospital Melbourne, Fitzroy","place":["VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Pertile","sequence":"additional","affiliation":[{"name":"Department of Haematology, St Vincent\u2019s Hospital Melbourne, Fitzroy","place":["VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[{"name":"The Australian Centre for Blood Diseases, Monash University, Melbourne","place":["VIC, Australia"]},{"name":"Department of Haematology, The Alfred Hospital, Melbourne","place":["VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17888","article-title":"Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period","volume":"196","author":"Rodr\u00edguez-Lobato","year":"2022","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.eclinm.2023.102017","article-title":"Impact of minimal residual disease standardised assessment by FDG-PET\/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial","volume":"60","author":"Zamagni","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20512","article-title":"Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders","volume":"78","author":"Paiva","year":"2010","journal-title":"Cytometry Part B Clin Cytometry"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma","volume":"119","author":"Paiva","year":"2012","journal-title":"Blood J Am Soc Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood J Am Soc Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"Van Dongen","year":"2012","journal-title":"Leukemia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/leu.2012.122","article-title":"EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols","volume":"26","author":"Kalina","year":"2012","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/bjh.15075","article-title":"Molecular detection of minimal residual disease in multiple myeloma","volume":"181","author":"Bai","year":"2018","journal-title":"Br J Haematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood J Am Soc Hematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood J Am Soc Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143687","article-title":"Minimal residual disease in multiple myeloma: past, present, and future","volume":"15","author":"Medina-Herrera","year":"2023","journal-title":"Cancers"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2023.12.009","article-title":"Measurable residual disease and decision-making in multiple myeloma","volume":"38","author":"Derman","year":"2024","journal-title":"Hematology\/Oncology Clinics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.02.005","article-title":"Association of minimal residual disease negativity rates with progression free survival in frontline therapy trials for newly diagnosed multiple myeloma: a meta-analysis","volume":"23","author":"Ficek","year":"2023","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma","volume":"10","author":"Medina","year":"2020","journal-title":"Blood Cancer J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102016","article-title":"Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing","volume":"60","author":"Oliva","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood J Am Soc Hematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3324\/haematol.2017.177139","article-title":"Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma","volume":"103","author":"Davies","year":"2018","journal-title":"Haematologica"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.00386","article-title":"Standardization of (18)F-FDG-PET\/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma","volume":"39","author":"Zamagni","year":"2021","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025030084","article-title":"Prognostic value of premaintenance FDG PET\/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial","volume":"146","author":"Kraeber-Bod\u00e9r\u00e9","year":"2025","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1182\/blood-2019-123143","article-title":"Evaluation of the prognostic value of positron emission tomography-computed tomography (PET-CT) at diagnosis and follow-up in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients treated in the phase 3 Cassiopeia study: results of the Cassiopet companion study","volume":"134","author":"Moreau","year":"2019","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-023-00794-x","article-title":"Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients","volume":"13","author":"Fonseca","year":"2023","journal-title":"Blood Cancer J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.740559","article-title":"Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging \u201cearly myeloma","volume":"54","author":"Hillengass","year":"2013","journal-title":"Leukemia Lymphoma"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.72.2975","article-title":"Prospective evaluation of magnetic resonance imaging and [18F] fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study","volume":"35","author":"Moreau","year":"2017","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d7953","article-title":"Circulating tumour cells (CTCs) in haematological malignancies: advances in biology and clinical relevance with a focus on multiple myeloma","volume":"208","author":"Hsu","year":"2026","journal-title":"Br J Haematol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.91","article-title":"Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial","volume":"52","author":"Huhn","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01393","article-title":"High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"40","author":"Bertamini","year":"2022","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma","volume":"40","author":"Garc\u00e9s","year":"2022","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002610","article-title":"Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy","volume":"134","author":"Sanoja-Flores","year":"2019","journal-title":"Blood J Am Soc Hematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029234","article-title":"Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment","volume":"146","author":"Lasa","year":"2025","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1038\/s41467-018-04001-5","article-title":"Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma","volume":"9","author":"Manier","year":"2018","journal-title":"Nat Commun"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2024.0424","article-title":"Clinical implications of circulating tumor DNA in multiple myeloma and its precursor diseases","volume":"45","author":"Park","year":"2025","journal-title":"Ann Lab Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.3390\/diagnostics12061305","article-title":"Digital droplet PCR in hematologic malignancies: a new useful molecular tool","volume":"12","author":"Galimberti","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.2015.1019476","article-title":"Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq","volume":"15","author":"Bratman","year":"2015","journal-title":"Expert Rev Mol Diagn"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2018.07.006","article-title":"Noninvasive molecular monitoring in multiple myeloma patients using cell-free tumor DNA: a pilot study","volume":"20","author":"Biancon","year":"2018","journal-title":"J Mol Diagn"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-2219","article-title":"Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma","volume":"146","author":"Kondapally","year":"2025","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70405","article-title":"Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing","volume":"10","author":"Buenache","year":"2026","journal-title":"HemaSphere"},{"key":"B50","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3324\/haematol.2023.283831","article-title":"Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients","volume":"109","author":"Mithraprabhu","year":"2024","journal-title":"Haematologica"},{"key":"B51","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1182\/blood-2023-186916","article-title":"Minimally invasive assessment of measurable residual disease (MRD) in multiple myeloma (MM)","volume":"142","author":"Gonzalez","year":"2023","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0469-x","article-title":"Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients","volume":"33","author":"Mithraprabhu","year":"2019","journal-title":"Leukemia"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19071858","article-title":"Circulating tumour DNA analysis for tumour genome characterisation and monitoring disease burden in extramedullary multiple myeloma","volume":"19","author":"Mithraprabhu","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3439544","article-title":"The utility of non-invasive liquid biopsy for mutational analysis and minimal residual disease assessment in extramedullary multiple myeloma","volume":"189","author":"Long","year":"2019"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-010-4361-9","article-title":"An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regions","volume":"399","author":"Dekker","year":"2011","journal-title":"Anal Bioanal Chem"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24772","article-title":"The utility of MASS\u2010FIX to detect and monitor monoclonal proteins in the clinic","volume":"92","author":"Milani","year":"2017","journal-title":"Am J Hematol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2015.253740","article-title":"Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry","volume":"62","author":"Mills","year":"2016","journal-title":"Clin Chem"},{"key":"B58","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jmsacl.2024.02.002","article-title":"Endogenous monoclonal immunoglobulins analyzed using the EXENT\u00ae solution and LC-MS","volume":"32","author":"Barnidge","year":"2024","journal-title":"J Mass Spectrom Adv Clin Lab"},{"key":"B59","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41408-019-0263-z","article-title":"Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement","volume":"9","author":"Murray","year":"2019","journal-title":"Blood Cancer J"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2015.242651","article-title":"Clonotypic light chain peptides identified for monitoring minimal residual disease in multiple myeloma without bone marrow aspiration","volume":"62","author":"Bergen","year":"2016","journal-title":"Clin Chem"},{"key":"B61","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41408-021-00408-4","article-title":"Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report","volume":"11","author":"Murray","year":"2021","journal-title":"Blood Cancer J"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-0649","article-title":"A personalized mass spectrometry\u2013based assay to monitor M-protein in patients with multiple myeloma (EasyM)","volume":"27","author":"Liyasova","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024995","article-title":"Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma","volume":"144","author":"Puig","year":"2024","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1182\/blood-2021-151557","article-title":"Assessment of treatment response by IFE, next generation flow cytometry and mass spectrometry coupled with liquid chromatography in the GEM2012MENOS65 clinical trial","volume":"138","author":"Puig","year":"2021","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3324\/haematol.2024.285933","article-title":"Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma","volume":"110","author":"Zhao","year":"2024","journal-title":"Haematologica"},{"key":"B66","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cca.2024.118538","article-title":"Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry","volume":"13","author":"Noori","year":"2023","journal-title":"Blood Cancer J"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19589","article-title":"Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002H CAR T\u2010cells","volume":"205","author":"Ortiz de Landazuri","year":"2024","journal-title":"Br J Haematol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v126.23.4191.4191","article-title":"Multiple myeloma (MM): Impact of immunoglobulin isotype on the speed of response","volume":"126","author":"Caillon","year":"2015","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016170","article-title":"MRD in multiple myeloma: does CR really matter","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood J Am Soc Hematol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.33.1967","article-title":"Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma","volume":"29","author":"Paiva","year":"2011","journal-title":"J Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1182\/blood-2023-190209","article-title":"Mass spectrometry-based assessment of M-protein in peripheral blood during maintenance therapy in multiple myeloma (MM) in the phase III ATLAS trial","volume":"142","author":"Kubicki","year":"2023","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis","volume":"20","author":"Avet-Loiseau","year":"2020","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010821","article-title":"Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma","volume":"8","author":"Paiva","year":"2024","journal-title":"Blood Adv"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000970708.04566.c4","article-title":"P951: Impact of measurable residual disease (mrd) differences on progression-free survival (pfs): an aggregate data analysis from randomized clinical trials in multiple myeloma (MM)","volume":"7","author":"Paiva","year":"","journal-title":"HemaSphere"},{"key":"B77","unstructured":"Minimal residual disease and complete response in multiple myeloma: use as endpoints to support accelerated approval. Draft guidance for industry\n          \n          \n          \n          2026"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000846612.13339.9e","article-title":"Time to response, duration of response, and patient-reported outcomes with daratumumab plus Rd vs Rd alone in transplant-ineligible patients with NDMM subgroup analysis of the phase 3 MAIA study","volume":"6","author":"Facon","year":"2022","journal-title":"HemaSphere"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the phase III randomized iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients","volume":"142","author":"Gay","year":"2023","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147897","article-title":"Daratumumab (DARA) with bortezomib, thalidomide, and dexamethasone (VTd) in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) negativity in Cassiopeia Part 1 and Part 2","volume":"138","author":"Loiseau","year":"2021","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02164-4","article-title":"Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial","volume":"59","author":"de Tute","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematology"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood J Am Soc Hematol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2023022083","article-title":"Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma","volume":"143","author":"Guerrero","year":"2024","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022080","article-title":"Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma","volume":"143","author":"D\u2019Agostino","year":"2024","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005822","article-title":"Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016782","article-title":"MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and-MM4 trials","volume":"141","author":"Paiva","year":"2023","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027686","article-title":"Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma","volume":"145","author":"Terpos","year":"2025","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41408-024-01156-x","article-title":"Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)","volume":"14","author":"Derman","year":"2024","journal-title":"Blood Cancer J"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019531","article-title":"Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma","volume":"142","author":"Rosi\u00f1ol","year":"2023","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12885-024-12077-0","article-title":"Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma","volume":"24","author":"Tao","year":"2024","journal-title":"BMC Cancer"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(21)00130-7","article-title":"Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial","volume":"8","author":"Diamond","year":"2021","journal-title":"Lancet Haematology"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18101569","article-title":"Sustained MRD Negative for 4 Years Is a Significant Marker of Prognosis in Patients with High-Risk Multiple Myeloma","volume":"18","author":"Liu","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B95","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood J Am Soc Hematol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1200\/jco.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J Clin Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01916","article-title":"Definition and clinical significance of the monoclonal gammopathy of undetermined significance\u2013like phenotype in patients with monoclonal gammopathies","volume":"41","author":"Burgos","year":"2023","journal-title":"J Clin Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02228","article-title":"Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk","volume":"40","author":"de Tute","year":"2022","journal-title":"J Clin Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-165376","article-title":"Defining the optimal duration of lenalidomide maintenance after autologous stem cell transplant-data from the Myeloma XI trial","volume":"140","author":"Pawlyn","year":"2022","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-142913","article-title":"Phase III study of daratumumab\/rhuph20 (nsc-810307)+ lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapyin patients with multiple myeloma (mm) using minimal residual disease todirect therapy duration (DRAMMATIC study): SWOG s1803","volume":"136","author":"Krishnan","year":"2020","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(26)00011-6","article-title":"Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial","volume":"13","author":"Dytfeld","year":"2026","journal-title":"Lancet Haematol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00738-0","article-title":"Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Dytfeld","year":"2023","journal-title":"Lancet Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025746","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study","volume":"145","author":"Badros","year":"2025","journal-title":"Blood"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.7500","article-title":"MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial","volume":"43","author":"Perrot","year":"2025","journal-title":"J Clin Oncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1182\/blood-2024-202079","article-title":"Advance multicenter clinical trial: Mrd-driven therapy in newly diagnosed multiple myeloma patients","volume":"142","author":"Landgren","year":"2023","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-063037","article-title":"Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II\/III randomised controlled trial","volume":"12","author":"Royle","year":"2022","journal-title":"BMJ Open"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2000.1","DOI":"10.1182\/blood-2024-200210","article-title":"MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial","volume":"144","author":"Dhakal","year":"2024","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1182\/blood-2023-189022","article-title":"Will Survival Improve By Treating Multiple Myeloma Patients at MRD Relapse? the Remnant Study","volume":"142","author":"Askeland","year":"2023","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood-2023-188844","article-title":"RADAR Trial: MRD Response Adapted Trial for Newly Diagnosed Transplant Eligible Myeloma Patients","volume":"142","author":"Ramasamy","year":"2023","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood J Am Soc Hematol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.2424","article-title":"Elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma without transplant intent: a phase 2 measurable residual disease\u2013adapted study","volume":"8","author":"Derman","year":"2022","journal-title":"JAMA Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01814","article-title":"Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR","volume":"39","author":"Avet-Loiseau","year":"2021","journal-title":"J Clin Oncol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/s2666-6367(22)00390-6","article-title":"Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma","volume":"13","author":"Bansal","year":"2023","journal-title":"Blood Cancer J"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.bcd-23-0044","article-title":"Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel","volume":"4","author":"Paiva","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"B121","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1182\/blood-2024-201533","article-title":"Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1\u20133 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial","volume":"31","author":"Popat","year":"2025","journal-title":"Transplant Cell Therapy Off Publ Am Soc For Transplant Cell Ther"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.70425","article-title":"Early Treatment Failure in Patients Receiving Ciltacabtagene\u2010Autoleucel for Relapsed\/Refractory Multiple Myeloma","volume":"101","author":"Lim","year":"2026","journal-title":"Am J Hematol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000970420.62475.d0","article-title":"Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"23","author":"van de Donk","year":"2023","journal-title":"Am Soc Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5814","article-title":"Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed\/refractory multiple myeloma","volume":"146","author":"Razzo","year":"2025","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1932648\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:01:25Z","timestamp":1790341285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1932648\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":124,"alternative-id":["10.3389\/fimmu.2026.1932648"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1932648","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1932648"}}